Zydus Lifesciences’ US office in New Jersey received a nil observation report from the USFDA after an inspection of its pharmacovigilance and post-marketing surveillance system.
Zydus Lifesciences’ US office in New Jersey received a nil observation report from the USFDA after an inspection of its pharmacovigilance and post-marketing surveillance system.